Aurobindo Pharma's Eugia Unit Gets 5 US FDA Observations

Inspection Details

The United States Food and Drug Administration (US FDA) conducted a Pre-Approval Inspection at Eugia Steriles Private Limited, which is a 100% subsidiary of Eugia Pharma Specialities Limited and a stepdown subsidiary of Aurobindo Pharma Limited. The inspection took place at the facility situated at Parawada Mandal, Anakapalli District, Andhra Pradesh. The inspection period was from June 10, 2026, to June 19, 2026.

Inspection Outcome

The inspection concluded with 5 observations. The company has stated that these observations will be responded to within the stipulated time frame.

Financial and Operational Impact

The company explicitly states that "There is no impact on the Company's financials or operations due to the said action." This indicates no quantifiable monetary impact from the inspection observations.

Future Communications

The company has committed to keeping the stock exchanges informed if there is any further information relating to this matter in the future.

#Tags: #AurobindoPharma #USFDA #RegulatoryCompliance #SEBIDisclosure #PharmaManufacturing #Neutral